Skip to main content
Clinical Trials/NCT04048252
NCT04048252
Completed
Not Applicable

Development of a Therapeutic Education Program for Patients With Metastatic Prostate Cancer Treated With New Generation Hormone Therapy: Construction and Feasibility Study

Centre Hospitalier Universitaire de Nīmes1 site in 1 country18 target enrollmentSeptember 10, 2019

Overview

Phase
Not Applicable
Intervention
Focus group creation
Conditions
Prostate Cancer
Sponsor
Centre Hospitalier Universitaire de Nīmes
Enrollment
18
Locations
1
Primary Endpoint
Create a focus group
Status
Completed
Last Updated
2 months ago

Overview

Brief Summary

The development of a personalized therapeutic education program dedicated to patients with metastatic prostate cancer and receiving next-generation hormone therapy would improve their knowledge of the disease, medication adherence and quality of life.

Registry
clinicaltrials.gov
Start Date
September 10, 2019
End Date
July 5, 2021
Last Updated
2 months ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Centre Hospitalier Universitaire de Nīmes
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Patients with metastatic prostate cancer treated with enzalutamide or abiraterone acetate for at least 3 months
  • The patient must have given their free and informed consent and signed the consent form
  • The patient must be insured or the beneficiary of an insurance policy

Exclusion Criteria

  • The subject is not in a fit state to express their consent
  • It is impossible to give the subject informed information
  • The patient is under safeguard of justice or state guardianship

Arms & Interventions

Focus group

Intervention: Focus group creation

Workshop

Intervention: Workshop

Outcomes

Primary Outcomes

Create a focus group

Time Frame: Day 0

Transcribe interview and mark key points

Patient satisfaction

Time Frame: End of workshops (max 2 months)

Yes/no

Successful running of workshop

Time Frame: End of workshops (max 2 months)

Yes/no evaluated by the workshop leader

Secondary Outcomes

  • Patient quality of life(1 month after last workshop)
  • Patient knowledge of their disease(End of workshops (max 2 months))
  • Patient-reported satisfaction of programme(End of workshops (max 2 months))
  • Patient-reported acceptability of programme(End of workshops (max 2 months))
  • Patient medication adherence(End of workshops (max 2 months))
  • Patient participation rate in workshops(End of workshops (max 2 months))

Study Sites (1)

Loading locations...

Similar Trials